TP53 and head and neck squamous cell carcinoma: A Phase III clinical trial for use of Advexin (adenovirus containing TP53) (INGN 201, Ad5CMV-p53) versus methotrexate in treating advanced recurrent HNSCC showed that patients with wild-type p53 had better response to Advexin, whereas patients carrying mutant p53 were more responsive to methotrexate chemotherapy which indicates the potential of p53 as a biomarker to design a targeted therapy [141].